EP1007650B1
(en)
|
1997-04-10 |
2009-03-18 |
Stichting Katholieke Universiteit University Medical Centre Nijmegen |
Pca3, pca3 genes, and methods of use
|
US7037667B1
(en)
|
1998-06-01 |
2006-05-02 |
Agensys, Inc. |
Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
|
US20030149531A1
(en)
|
2000-12-06 |
2003-08-07 |
Hubert Rene S. |
Serpentine transmembrane antigens expressed in human cancers and uses thereof
|
WO1999062941A2
(en)
|
1998-06-01 |
1999-12-09 |
Urogenesys, Inc. |
Serpentine transmembrane antigens expressed in human cancers and uses thereof
|
US6833438B1
(en)
|
1999-06-01 |
2004-12-21 |
Agensys, Inc. |
Serpentine transmembrane antigens expressed in human cancers and uses thereof
|
ES2260059T3
(en)
|
1999-09-29 |
2006-11-01 |
Diagnocure Inc. |
RNA MESSENGER OF PCA3 IN BENIGN AND MALIGNED PROSTATE FABRICS.
|
US7361338B2
(en)
|
1999-10-05 |
2008-04-22 |
Agensys, Inc. |
Methods to inhibit growth of prostate cancer cells
|
US6790631B1
(en)
|
1999-10-05 |
2004-09-14 |
Agensys, Inc. |
G protein-coupled receptor up-regulated in prostate cancer and uses thereof
|
US20020048777A1
(en)
|
1999-12-06 |
2002-04-25 |
Shujath Ali |
Method of diagnosing monitoring, staging, imaging and treating prostate cancer
|
US20090176722A9
(en)
|
2000-01-28 |
2009-07-09 |
Shiv Srivastava |
Androgen-regulated PMEPA1 gene and polypeptides
|
CA2417671A1
(en)
*
|
2000-07-28 |
2002-02-07 |
Ulrich Wissenbach |
Trp8, trp9 and trp10, novel markers for cancer
|
CA2432639A1
(en)
|
2000-11-16 |
2002-05-23 |
Cemines, Llc |
Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
|
WO2002060953A2
(en)
|
2000-12-15 |
2002-08-08 |
Agensys, Inc. |
Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
|
EP1356049A2
(en)
*
|
2000-12-15 |
2003-10-29 |
Millennium Pharmaceuticals, Inc. |
Human sugar transporter proteins, potassium channel proteins, phospholipid transporter proteins and methods of use thereof
|
US7118912B2
(en)
*
|
2002-08-26 |
2006-10-10 |
Case Western Reserve University |
Methods and compositions for categorizing patients
|
US20060035237A1
(en)
|
2002-08-26 |
2006-02-16 |
Markowitz Sanford D |
Methods and compositions for categorizing patients
|
US7081516B2
(en)
|
2002-08-26 |
2006-07-25 |
Case Western Reserve University |
Methods for categorizing patients
|
JP2004531241A
(en)
*
|
2001-03-05 |
2004-10-14 |
アベンティス・ファーマ・ソシエテ・アノニム |
Human ABCC11 gene nucleic acids, vectors containing such nucleic acids, and uses thereof
|
AU2002318112B2
(en)
|
2001-04-10 |
2007-12-06 |
Agensys, Inc. |
Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
|
US6897024B2
(en)
|
2001-05-31 |
2005-05-24 |
Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen |
Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
|
KR100576674B1
(en)
|
2001-06-20 |
2006-05-10 |
제넨테크, 인크. |
Compositions and Methods for the Diagnosis and Treatment of Tumor
|
US20050272120A1
(en)
|
2001-06-20 |
2005-12-08 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CA2458915A1
(en)
|
2001-08-31 |
2003-03-13 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer
|
JP2005505271A
(en)
|
2001-09-06 |
2005-02-24 |
アジェンシス, インコーポレイテッド |
Nucleic acids and corresponding proteins given the name STEAP-1 useful in the treatment and detection of cancer
|
US7494646B2
(en)
|
2001-09-06 |
2009-02-24 |
Agensys, Inc. |
Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
|
WO2003076565A2
(en)
*
|
2001-09-17 |
2003-09-18 |
Millennium Pharmaceuticals, Inc. |
Methods of using 46828, a human acyl-coa synthetase
|
US20030100034A1
(en)
*
|
2001-10-16 |
2003-05-29 |
Millennium Pharmaceuticals, Inc. |
9136, a human aldehyde dehydrogenase family member and uses therefor
|
CA2470088A1
(en)
*
|
2001-12-20 |
2003-07-03 |
Tularik Inc. |
Identification of an amplified gene and target for drug intervention
|
WO2003070889A2
(en)
*
|
2002-02-19 |
2003-08-28 |
Idec Pharmaceuticals Corporation |
Prostate specific genes and the use thereof in design or therapeutics
|
WO2005067629A2
(en)
*
|
2004-01-06 |
2005-07-28 |
Avalon Pharmaceuticals |
Cancer-linked genes as targets for chemotherapy
|
US20040162236A1
(en)
*
|
2002-04-01 |
2004-08-19 |
John Alsobrook |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
EP1361433A3
(en)
*
|
2002-04-09 |
2005-02-23 |
Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo |
Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
|
AU2003231196C1
(en)
*
|
2002-05-10 |
2009-05-21 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Androgen-regulated PMEPA1 and cancer
|
DE10234901A1
(en)
*
|
2002-07-26 |
2004-02-12 |
Metagen Pharmaceuticals Gmbh |
New nucleic acids encoding Mrp4, useful in the diagnosis of prostatic, bladder and ovarian tumors, also in screening for specific binding agents, and potential therapeutic agents
|
EP1534833A4
(en)
*
|
2002-08-09 |
2006-06-07 |
Melbourne Health |
Mammalian grainyhead transcription factors
|
WO2004016733A2
(en)
|
2002-08-16 |
2004-02-26 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
|
WO2004018648A2
(en)
*
|
2002-08-26 |
2004-03-04 |
Case Western Reserve University |
Methods for treating patients and identifying therapeutics
|
WO2004053495A1
(en)
*
|
2002-12-09 |
2004-06-24 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with phosphodiesterase 9a1 (pde9a1)
|
AU2004209578A1
(en)
|
2003-02-07 |
2004-08-19 |
Diagnocure Inc. |
Method to detect prostate cancer in a sample
|
JP2004357702A
(en)
*
|
2003-05-09 |
2004-12-24 |
Research Association For Biotechnology |
New protein and dna encoding the same
|
US7473531B1
(en)
|
2003-08-08 |
2009-01-06 |
Colora Corporation |
Pancreatic cancer targets and uses thereof
|
US7294704B2
(en)
|
2003-08-15 |
2007-11-13 |
Diadexus, Inc. |
Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
|
ES2579836T3
(en)
|
2003-11-06 |
2016-08-17 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation with ligands
|
WO2005083086A2
(en)
*
|
2004-02-27 |
2005-09-09 |
Oncotherapy Science, Inc. |
Epha4 as therapeutic target of prc and pdaca
|
CA2563735C
(en)
|
2004-04-22 |
2020-07-14 |
Agensys, Inc. |
Antibodies and molecules derived therefrom that bind to steap-1 proteins
|
WO2005106488A2
(en)
*
|
2004-04-28 |
2005-11-10 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with g protein-coupled beta-2 adrenoceptor (adrb2)
|
AU2005249490B2
(en)
|
2004-06-01 |
2010-07-29 |
Genentech, Inc. |
Antibody drug conjugates and methods
|
EP1794314A2
(en)
*
|
2004-07-23 |
2007-06-13 |
Bayer HealthCare AG |
Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1)
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
CA2580141C
(en)
|
2004-09-23 |
2013-12-10 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
WO2006060533A2
(en)
|
2004-12-01 |
2006-06-08 |
Genentech, Inc. |
Conjugates of 1, 8-bis-naphthalimides with an antibody
|
CA2491067A1
(en)
|
2004-12-24 |
2006-06-24 |
Stichting Katholieke Universiteit |
Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
|
WO2006074914A2
(en)
*
|
2005-01-13 |
2006-07-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Human rna helicase and therapeutic uses thereof
|
ES2459466T3
(en)
|
2005-02-25 |
2014-05-09 |
Oncotherapy Science, Inc. |
Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
|
KR101541550B1
(en)
|
2006-10-27 |
2015-08-04 |
제넨테크, 인크. |
Antibodies and immunoconjugates and uses therefor
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
EP2171090B1
(en)
*
|
2007-06-08 |
2013-04-03 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
AU2008296927C1
(en)
*
|
2007-09-06 |
2015-08-13 |
Case Western Reserve University |
Methods for diagnosing and treating cancers
|
JP5589274B2
(en)
*
|
2007-10-25 |
2014-09-17 |
東レ株式会社 |
Immune inducer
|
AU2014240339B2
(en)
*
|
2007-10-25 |
2017-07-13 |
Toray Industries, Inc. |
Method for detection of cancer
|
PT3106874T
(en)
*
|
2007-10-25 |
2020-05-08 |
Toray Industries |
Method for detection of cancer
|
ES2532635T3
(en)
|
2008-07-15 |
2015-03-30 |
Genentech, Inc. |
Anthracycline conjugates, process for its preparation and its use as antitumor compounds
|
TWI543767B
(en)
|
2008-08-19 |
2016-08-01 |
腫瘤療法 科學股份有限公司 |
Hig2 and urlc10 epitope peptide and vaccines containing the same
|
TW201008574A
(en)
|
2008-08-19 |
2010-03-01 |
Oncotherapy Science Inc |
INHBB epitope peptides and vaccines containing the same
|
JP2013504585A
(en)
|
2009-09-09 |
2013-02-07 |
セントローズ, エルエルシー |
Extracellular targeted drug complex
|
MX2012011901A
(en)
|
2010-04-15 |
2012-11-29 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof.
|
JP2013533732A
(en)
*
|
2010-05-03 |
2013-08-29 |
ジェネンテック, インコーポレイテッド |
Compositions and methods for tumor diagnosis and treatment
|
CA3220104A1
(en)
|
2010-06-08 |
2011-12-15 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
CN103313990B
(en)
|
2010-11-17 |
2016-07-20 |
基因泰克公司 |
Alanyl maytansinol antibody coupling matter
|
EP2707723B1
(en)
|
2011-05-12 |
2016-02-10 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
|
MX350152B
(en)
|
2011-10-14 |
2017-08-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof.
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
ES2680153T3
(en)
|
2012-10-12 |
2018-09-04 |
Adc Therapeutics Sa |
Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
|
US10751346B2
(en)
|
2012-10-12 |
2020-08-25 |
Medimmune Limited |
Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
|
CA2887897C
(en)
|
2012-10-12 |
2020-02-18 |
Adc Therapeutics Sarl |
Pyrrolobenzodiazepine-anti-cd25 antibody conjugates
|
PL2839860T3
(en)
|
2012-10-12 |
2019-10-31 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
EP2906297B1
(en)
|
2012-10-12 |
2017-12-06 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-antibody conjugates
|
HUE035694T2
(en)
|
2012-10-12 |
2018-05-28 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
|
US9931414B2
(en)
|
2012-10-12 |
2018-04-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
CN105246894A
(en)
|
2012-12-21 |
2016-01-13 |
斯皮罗根有限公司 |
Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
|
US9562049B2
(en)
|
2012-12-21 |
2017-02-07 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
CA2904044C
(en)
|
2013-03-13 |
2020-03-31 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
BR112015023333A8
(en)
|
2013-03-13 |
2018-04-17 |
Medimmune Ltd |
pyrrolbenzodiazepines and conjugates thereof
|
SG11201507214SA
(en)
|
2013-03-13 |
2015-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2014144657A2
(en)
*
|
2013-03-15 |
2014-09-18 |
Metamark Genetics, Inc. |
Compositions and methods for cancer prognosis
|
MX2016001862A
(en)
|
2013-08-12 |
2016-08-03 |
Genentech Inc |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.
|
WO2015052532A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
US9950078B2
(en)
|
2013-10-11 |
2018-04-24 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2015052535A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
CR20160271A
(en)
|
2013-12-16 |
2016-12-02 |
Genentech Inc |
PEPTIDOMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES
|
EP3082874A2
(en)
|
2013-12-16 |
2016-10-26 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
MX2016007578A
(en)
|
2013-12-16 |
2016-10-03 |
Genentech Inc |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.
|
US20150252425A1
(en)
*
|
2014-03-05 |
2015-09-10 |
Caldera Health Ltd. |
Gene expression profiling for the diagnosis of prostate cancer
|
JP6531166B2
(en)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドMedImmune Limited |
Pyrrolobenzodiazepine and its conjugate
|
CN106714844B
(en)
|
2014-09-12 |
2022-08-05 |
基因泰克公司 |
Anthracycline disulfide intermediates, antibody-drug conjugates and methods
|
BR112017003236A2
(en)
|
2014-09-12 |
2017-11-28 |
Genentech Inc |
cysteine engineered antibodies, drug conjugates and antibodies, drug and antibody conjugate preparation method and pharmaceutical composition
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
AU2015317653A1
(en)
|
2014-09-17 |
2017-04-06 |
Genentech, Inc. |
Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
|
CN107148285B
(en)
|
2014-11-25 |
2022-01-04 |
Adc治疗股份有限公司 |
Pyrrolobenzodiazepine-antibody conjugates
|
MX2017007169A
(en)
|
2014-12-03 |
2018-05-02 |
Genentech Inc |
Quaternary amine compounds and antibody-drug conjugates thereof.
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201510684D0
(en)
*
|
2015-06-17 |
2015-08-05 |
Almac Diagnostics Ltd |
Gene signatures predictive of metastatic disease
|
MA43345A
(en)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
|
MA43354A
(en)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
|
MA45326A
(en)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
EP3433621A1
(en)
|
2016-03-25 |
2019-01-30 |
H. Hoffnabb-La Roche Ag |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
EP3458101B1
(en)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac antibody conjugates and methods of use
|
WO2017205741A1
(en)
|
2016-05-27 |
2017-11-30 |
Genentech, Inc. |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
EP3464280B1
(en)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol antibody-drug conjugates and methods of use
|
CN109689111B
(en)
|
2016-08-11 |
2024-04-05 |
基因泰克公司 |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
CN110139674B
(en)
|
2016-10-05 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
Method for preparing antibody drug conjugates
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
DK3544636T3
(en)
|
2017-02-08 |
2021-05-10 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine antibody conjugates
|
JP7247101B2
(en)
|
2017-04-03 |
2023-03-28 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Antibody that binds to STEAP-1
|
DK3612537T3
(en)
|
2017-04-18 |
2022-08-08 |
Medimmune Ltd |
PYRROLOBENZODIAZEPIN CONJUGATES
|
PL3612234T3
(en)
|
2017-04-20 |
2024-09-02 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
EP3638373B1
(en)
|
2017-06-14 |
2024-09-04 |
ADC Therapeutics SA |
Dosage regimes for the administration of an anti-cd19 adc
|
ES2906965T3
(en)
|
2017-08-18 |
2022-04-21 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
EP3684773A1
(en)
|
2017-09-20 |
2020-07-29 |
pH Pharma Co., Ltd. |
Thailanstatin analogs
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
US20210318324A1
(en)
*
|
2018-07-05 |
2021-10-14 |
The Board Of Regents Of The University Of Oklahoma |
Gene signatures for cancer characterization and methods of use
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
EP3870235A1
(en)
|
2018-10-24 |
2021-09-01 |
F. Hoffmann-La Roche AG |
Conjugated chemical inducers of degradation and methods of use
|
GB201818576D0
(en)
*
|
2018-11-14 |
2018-12-26 |
Io Biotech Aps |
Arginase 2 polypeptides
|
CN113227119A
(en)
|
2018-12-10 |
2021-08-06 |
基因泰克公司 |
Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
WO2024138128A2
(en)
|
2022-12-23 |
2024-06-27 |
Genentech, Inc. |
Cereblon degrader conjugates, and uses thereof
|